buoyantintelligence
  • 01Overview
  • 02Portfolio
  • 03Company Atlas
    • Buoyant book
    • All listed companies
  • 04Screener & valuation
  • 05House view
  • 06Markets
  • 07India top-down
  • 08Investors
  • 09Library & data
Release
August 2026 · rev 1
Opportunities PMS · Published
As at 31 Aug 2026 · IST₹ · ₹ cr · BSE 500 TRI
Present
Internal working platform. Published figures are extracted from the August 2026 source package and reviewed; reference prices and fundamentals are unlicensed working data, not for redistribution. Past performance is not indicative of future returns.
All listed companies/CORONA Remedies Limited
03 /Listed universe · Healthcare · Pharmaceuticals

CORONA Remedies Limited.

Value itCompareScreener.in ↗Tijori ↗NSE ↗BSE ↗
Snapshot

Healthcare · Pharmaceuticals

CORONA Remedies Limited, a pharmaceutical formulation company, develops, manufactures, and markets pharmaceutical products. It provides products in women's healthcare, cardio-diabeto, pain management, urology, thyroid management, respiratory, nutraceuticals, gastroenterology, and other therapeutic areas. The company was incorporated in 2004 and is based in Ahmedabad, India.

Market cap
₹13,354 cr
P/E (TTM)
67.1
P/B (latest)
17.9
ROE (TTM)
24.8%
ROCE (TTM)
31.5%
Sales CAGR 3y
16.7%
PAT CAGR 3y
29.7%
Debt / equity
0.19x
Promoter
69%
Dividend yield
0.46%
Size
Micro
Codes
CORONA · 544644
Price

₹2,085 · 29 Sept 2026

1M
+0.3%
3M
+5.9%
6M
+31.8%
YTD
+48.7%
1Y
—
3Y
—
5Y
—
vs 52w high
−6.8%

52-week ₹1,347.7 – ₹2,236.1 · ADTV ₹8.7 cr · price-only.

Trend

Sales and net profit by fiscal year, ₹ crore

Not in the Buoyant book: no house thesis or target is carried. Exchange masters, Tijori and the reference price feed as stated on each tab. All listed companies · NSE EQ